Shots:

• Halozyme will discontinue its P-III HALO-301 study evaluating PEGPH20 in combination with gemcitabine and nab-paclitaxel (Abraxane) vs gemcitabine and nab-paclitaxel as a 1L therapy for the treatment of patients with metastatic pancreatic cancer
• The P-III HALO-301 study results: did not meet its 1EPs of OS (11.2 vs 11.5mos.) as there was a higher response rate but it did not translate into an improvement in DOR- PFS or OS
• The discontinuation of all the development activities for PEGPH20 and allow Halozyme to focus solely on its ENHANZE drug delivery technology

Click here to­ read full press release/ article | Ref: Halozyme | Image: SPJ News